T Cell News and Research

Latest T Cell News and Research

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

4 Mar 2010

Top ten beauty treatments

RoxSpa, one of the most prestigious and luxurious medi-spas in Beverly Hills, announces their annual 'Top Ten' face and body rejuvenation treatments that are both highly-effective and provide the most satisfying results.

4 Mar 2010

Study shows inhibiting critical genes may halt leukaemia cell growth

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells.

4 Mar 2010

Mosaic vaccines show promise in reducing HIV spread

Two teams of researchers-including Los Alamos National Laboratory theoretical biologists Bette Korber, Will Fischer, Sydeaka Watson, and James Szinger-have announced an HIV vaccination strategy that has been shown to expand the breadth and depth of immune responses in rhesus monkeys. Rhesus monkeys provide the best animal model currently available for testing HIV vaccines.

4 Mar 2010

Severe inflammatory diseases: Blocking "death messenger" might be a promising treatment

The signaling molecule CD95L, known as "death messenger," causes an inflammatory process in injured tissue after spinal cord injuries and prevents its healing. This discovery was published by scientists of the German Cancer Research Center. In mice, the researchers found out that if they switch off CD95L, the injured spinal cord heals and the animals regain better ability to move. Therefore, substances which block the death messenger might offer a new approach in the treatment of severe inflammatory diseases.

4 Mar 2010

MIT Technology Review recognizes Medtronic for taking leadership in developing DBS Therapy

Medtronic, Inc. today announced that it has been selected as one of Massachusetts Institute of Technology Technology Review's 50 most innovative companies. Known as TR50, the first annual list includes companies that Technology Review believes have demonstrated superiority in inventing technology and in using it both to grow their own business and transform how we live.

4 Mar 2010

Boosting immune response to vaccinations: Role of aluminium adjuvants

An imminent publication in Trends in Immunology by a leading researcher in the bioinorganic chemistry of aluminium, Dr Christopher Exley, Reader in Bioinorganic Chemistry at The Birchall Centre, Keele University in Staffordshire, has now gone some way to giving the fullest possible explanation of how aluminium adjuvants work in boosting the immune response to vaccination.

4 Mar 2010

Exposure to blue-violet light may enhance cell growth in wound sites

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher C. Millan (U.S. Army Dental Corps, Martinez, Georgia) will present a poster of a study titled "A Novel In Vitro Model for Light-Induced Wound Healing."

4 Mar 2010

Using high-resolution CT-scans to screen for LAM is cost-effective in non-smoking women

Researchers at the University of Cincinnati have found that using high-resolution CT-scans to screen for lymphangioleiomyomatosis, or LAM, is cost-effective in non-smoking women between 25 and 54 who come to the emergency room for the first time with a collapsed lung.

4 Mar 2010

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.

4 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

Researchers demonstrate the safety of potential vaccine against mesothelioma

Researchers have demonstrated the safety of a potential vaccine against mesothelioma, a rare cancer associated primarily with asbestos exposure. The vaccine, which infuses uses a patient's own dendritic cells (DC) with antigen from the patient's tumor, was able to induce a T-cell response against mesothelioma tumors.

4 Mar 2010

Corning commercializes new Synthemax synthetic surface for supporting growth and differentiation of stem cells

Corning Incorporated today introduced the Corning® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells. The surface is being commercialized as a result of Corning’s ongoing collaboration with Geron Corporation. This development enables researchers to take the next step toward scalable and cost-effective manufacturing of stem cells for potential therapies in the treatment of degenerative diseases.

4 Mar 2010

Belatacept drug can prevent graft rejection in kidney transplant recipients

The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.

4 Mar 2010

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.

4 Mar 2010

Lemelson-MIT Collegiate Student Prizes awarded to inventive students nationwide

A scientific "Renaissance man" whose work spans the fields of mathematics, linguistics, biotechnology and polymer physics, Erez Lieberman-Aiden, graduate student at the Harvard-MIT Division of Health Sciences and Technology, has been named the winner of the prestigious $30,000 Lemelson-MIT Student Prize. Lieberman-Aiden, one of four 2010 $30,000 Lemelson-MIT Collegiate Student Prize winners announced today, was selected for the breadth and depth of his innovations.

4 Mar 2010

Researchers explore molecular origin of skin and hair to develop novel beauty products

Scientists at L'Or-al, in hot pursuit of the hidden elements of beauty, seem well on their way to disputing the old adage, "beauty is only skin deep." In fact, their work indicates that what makes hair curly or straight and skin smooth or rough, is much deeper.

3 Mar 2010

CaridianBCT's Trima Accel Automated Blood Collection System Version 6.0 receives 510(k) clearance

CaridianBCT, a leading global provider of technology, products and services in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies announced it has received 510(k) clearance for the Trima Accel® Automated Blood Collection System Version 6.0—providing increased efficiencies and streamlined operations to blood centers.

3 Mar 2010

Gene 'addiction' of leukaemia cells

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.

3 Mar 2010

T Cell News and Research

Latest T Cell News and Research

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Top ten beauty treatments

Study shows inhibiting critical genes may halt leukaemia cell growth

Mosaic vaccines show promise in reducing HIV spread

Severe inflammatory diseases: Blocking "death messenger" might be a promising treatment

MIT Technology Review recognizes Medtronic for taking leadership in developing DBS Therapy

Boosting immune response to vaccinations: Role of aluminium adjuvants

Exposure to blue-violet light may enhance cell growth in wound sites

Using high-resolution CT-scans to screen for LAM is cost-effective in non-smoking women

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Researchers demonstrate the safety of potential vaccine against mesothelioma

Corning commercializes new Synthemax synthetic surface for supporting growth and differentiation of stem cells

Belatacept drug can prevent graft rejection in kidney transplant recipients

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Lemelson-MIT Collegiate Student Prizes awarded to inventive students nationwide

Researchers explore molecular origin of skin and hair to develop novel beauty products

CaridianBCT's Trima Accel Automated Blood Collection System Version 6.0 receives 510(k) clearance

Gene 'addiction' of leukaemia cells

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in